Antiviral Activity of AZD7295 in HCV Carriers
- Registration Number
- NCT00781976
- Lead Sponsor
- Arrow Therapeutics
- Brief Summary
PK, safety study of AZD7295 in HCV carriers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Inclusion Criteria
- HCV carrier
Exclusion Criteria
- concurrent medications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Placebo - 2 AZD7295 -
- Primary Outcome Measures
Name Time Method Plasma AZD7295 concentrations and pharmacokinetics 5 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie AZD7295's antiviral activity against HCV in phase 1 trials?
How does AZD7295 compare to standard-of-care HCV treatments in terms of efficacy and safety profiles?
Are there specific biomarkers that correlate with response to AZD7295 in HCV-infected patients with compensated liver disease?
What adverse events were observed in NCT00781976 and how were they managed in HCV carriers?
What are the current combination therapies involving AZD7295 for HCV and how do they compare to competitor drugs?
Trial Locations
- Locations (1)
Prof Ed Gane
🇳🇿Auckland, New Zealand
Prof Ed Gane🇳🇿Auckland, New Zealand